道斯达尔 Maziar Mike Doustdar — 诺和诺德 CEO
FORTUNE 500 #368

道斯达尔

Maziar Mike Doustdar

诺和诺德 (Novo Nordisk)

领导丹麦大型制药企业运营

广告

专业领域

医疗保健管理 运营优化

Health Care management, operations optimization

核心贡献

领导丹麦大型制药企业运营

Leading large-scale Pharmaceuticals operations in Denmark

最新观点

  • Novo Nordisk Company Announcement / Reuters · 2026-11-04 阅读原文

    杜斯达在Q3财报中表示业绩超预期并上调全年指引,增长由肥胖症组合驱动——Wegovy口服片在美持续放量、国际市场早期上市表现鼓舞人心,公司正准备2027年初在美国上市CagriSema;他同时向路透表示,自礼来推出竞品口服药后诺和诺德“守住了接力棒”,Wegovy在美国品牌肥胖药市场新患者处方份额仍超50%。

    We delivered a stronger-than-expected third quarter and are raising our full-year outlook. Growth was led by our obesity portfolio, with continued uptake of Wegovy pill in the US and encouraging early launches internationally. We are also preparing for the US launch of CagriSema in early 2027. We've been able to hold the baton since Lilly launched a rival pill, with the Wegovy franchise maintaining more than 50% share in new patient starts in the branded obesity market.

广告